Financial News

Financial Report: West Pharmaceutical Services

Proprietary Products Segment sales grew 6% to $345.2 million in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

West Pharmaceutical Services 3Q Revenues: $456.1 million (+6%) 3Q Earnings: $56.3 million (+2%) YTD Revenues: $1.4 billion (+6%) YTD Earnings: $177.8 million (+15%) Comments: Proprietary Products Segment sales grew 6% to $345.2 million. Biologics market unit sales growth was led by NovaPure, Daikyo and Flurotec components as well as products incorporating Daikyo’s Crystal Zenith technology. Generics market unit sales growth was led by sales of Daikyo components, products incorporating...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters